Trial Profile
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Bladder cancer vaccine (Primary) ; Bladder cancer vaccine (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-676
- Sponsors Merck Sharp & Dohme Corp.
- 19 Feb 2024 According to Trial design presented at the 2024 Genitourinary Cancers Symposium, enrollment incohort A of KEYNOTE-676 is ongoing in Asia, Australia, Europe, and North America.
- 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
- 19 Feb 2022 Trial design presented at the 2022 Genitourinary Cancers Symposium